SCHEMBL2967620

SCHEMBL2967620

Brc1ccc2c(c1)C=C(c1ccccc1)C2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.45
CYP11B2 P19099 4/20 0.42
CYP11B1 P15538 3/20 0.42
CYP19A1 P11511 2/20 0.41
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PNMT P11086 1/20 0.33
IP6K1 Q92551 1/20 0.33
IP6K3 Q96PC2 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
CA6 P23280 1/20 0.33
DCLK1 O15075 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
CHEK2 O96017 1/20 0.33
CSF1R P07333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2964136 0.86 CYP11B1 (0.42) TRPA1CYP11B2CYP11B1CYP19A1ALDH1A1
Hydrochloric Acid SCHEMBL28814933 0.79 CYP11B2 (0.46) CYP11B2CYP11B1CYP19A1ALDH1A1IP6K1
SCHEMBL16516818 0.78 CYP11B2 (0.53) TRPA1CYP11B2CYP11B1CYP19A1ALDH1A1
SCHEMBL31608568 0.77 CYP11B2 (0.65) TRPA1CYP11B2CYP11B1CYP19A1IP6K1
SCHEMBL319265 0.77 CYP11B2 (0.65) TRPA1CYP11B2CYP11B1CYP19A1IP6K1
SCHEMBL28814932 0.76 CYP11B1 (0.41) CYP11B2CYP11B1CYP19A1ALDH1A1IP6K1
SCHEMBL31666281 0.75 CYP11B2 (0.62) TRPA1CYP11B2CYP11B1CYP19A1IP6K1
SCHEMBL19432718 0.75 MMP3 (0.48) CYP11B2CYP11B1CYP19A1TDP2
SCHEMBL2958353 0.74 TRPA1 (0.39) TRPA1ALDH1A1TDP1L3MBTL1CA1
SCHEMBL2958175 0.73 PIK3R1 (0.42) TRPA1ALDH1A1TDP1L3MBTL1CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9905777-B2 Compound and organic electroluminescence device comprising same DOOSAN CORPORATION (KR) 2018-02-27 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150246902-A1 SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2015-09-03 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236271-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-7763562-B2 Heteroatom bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2010-07-27 US disclosed
US-20070135597-A1 Heteroatom bridged metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. 2007-06-14 US disclosed
WO-2006065809-A2 HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION EXXONMOBIL CHEMICAL PATENTS INC. (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246902-A1 SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES EIF5B, EIF2AK2, HCCS TRPA1 3845/4885CYP11B2 371/4885CYP11B1 298/4885
US-20070135597-A1 Heteroatom bridged metallocene compounds for olefin polymerization AP2M1, AP1M1, PYM1 TRPA1 438/4885CYP11B2 3583/4885CYP11B1 3696/4885
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 TRPA1 14/4885CYP11B2 653/4885CYP11B1 774/4885
US-20150236271-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME OR10J3, VDAC1, VDAC2 TRPA1 11/4885CYP11B2 2636/4885CYP11B1 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.